Newsgroup: it.economia.borsa
Titolo: CELL (ECCO L'INTERIM ANALISYS)

15 percent) was seen as well as clinically significant reductions in
infections and thrombocytopenia. In addition a significant reduction in
febrile neutropenia was also observed. Febrile neutropenia is a
life-threatening complication of chemotherapy which often requires
hospitalization and antibiotic therapy and may lead to death from infection
while the patient's infection-fighting white blood cells are low due to
neutropenia. The RAPID study is expected to complete enrollment in 2008.
      "We are excited by these results demonstrating that pixantrone is
living up to the promise of preventing the severe cardiac damage that
accompanies the use of standard doxorubicin treatment while retaining the
potent anti-lymphoma activity of this class of drug," said James A. Bianco,
M.D., President and CEO of CTI. "Pending results from this and other
studies, these findings could have major implications for treating patients
with breast cancer, lymphoma, and leukemia, where debilitating cardiac
damage from doxorubicin might be prevented. We look forward to discussing
these results and our planned interim analysis of the PIX301 (EXTEND)
pivotal trial with the FDA. We believe the RAPID data coupled with the
EXTEND data may provide sufficient clinical information for review of
pixantrone in aggressive NHL."
      Details of the RAPID Trial
      The RAPID (Replacing Adriamycin with Pixantrone to Improve Safety in
NHL Disease) trial is a 280-patient randomized controlled phase II/III
combination study investigating whether the substitution of pixantrone for
doxorubicin in the first-line treatment of patients with advanced aggressive
NHL can provide a comparable major response rate while reducing known
doxorubicin-related toxicities. This multi-center international trial
randomizes newly diagnosed patients to either the standard of care regimen
CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, and
rituximab) or an investigational regimen which replaces doxorubicin with
pixantrone, CPOP-R (cyclophosphamide, pixantrone, vincristine, prednisone,
and rituximab) monthly for six cycles. Patients are evaluated for response
to therapy every two cycles and evaluated every two months following
completion of therapy.
      Cardiac function, as determined by serial multi-gated nuclear scans
(MUGA), is evaluated prior to initiation of therapy and then at the
completion of every two cycles of therapy. Thus far, routine prophylactic
administration of G-CSF was utilized equally across treatment arms in
approximately half of study participants. The interim analysis was conducted
after approximately 60 patients completed at least four cycles of therapy to
determine if the dose of pixantrone (150 mg/m2) was adequate to induce major
objective responses comparable to the doxorubicin arm as well as to evaluate
potential differences in major toxicities.
      Pixantrone in Clinical Studies
      There are currently two clinical studies of pixantrone in aggressive
NHL patients, RAPID and a phase III single agent trial, known as EXTEND. The
EXTEND trial explores the role of single-agent treatment as a salvage
regimen in patients with relapsed aggressive NHL who have failed at least
two prior treatment regimens. Patients are randomized to receive either
pixantrone or another single-agent drug of the physician's choice currently
used for the treatment of this patient population. An interim look for the
EXTEND trial is planned for later this year.
      The Company is awaiting feedback from the FDA on the design of a new
phase III trial of pixantrone for patients with indolent NHL. The trial,
PIX303, will examine the complete remission rates and time to disease
progression for the combination regimen of fludarabine, pixantrone and
rituximab (FP-R) compared to the combination of fludarabine and rituximab
(F-R) in the treatment of patients who have received at least one prior
treatment for NHL. The trial is expected to enroll 300 patients.

 ha scritto nel messaggio
news:469492e0$0$4797$4faf...@reader4.news.tin.it...

bene ora pero mi sa che scendera' sell on news !!......anche perche mi pare
non ci sia + niente ina rrivo per i prossimi mesi ?!?!

Cell Therapeutics, positivi i test su utilizzo pixantrone
----------------------------------------------------------------------------
----
Cell Therapeutics ha reso noto che i risultati interim dello studio clinico
di fase II/III in cui il pixantrone sostituisce la doxorubicina del
protocollo standard CHOP-R nel trattamento di prima linea dei pazienti
affetti da linfoma aggressivo, dimostrano sostanzialmente che tutti i
pazienti di entrambi i gruppi hanno raggiunto una rilevante e oggettiva
risposta anti-tumorale (risposta completa o parziale).
La societą si appresta a discutere con la FDA questi risultati, nonchč la
prevista analisi interim dello studio clinico pilota Pix30 (EXTEND).

 non ci sia + niente ina rrivo per i prossimi mesi ?!?!
l'extend trial
 risultati preclinici bisplatinum (altro filone di ricerca futuro) (forse
già ad aprile, oppure dopo estate)
- risultati ct-2106 ovarian fase II (forse già ad aprile, oppure dopo
estate)
- risultati ct-2106 colorectal fase II (forse già ad aprile, oppure dopo
estate)
- risultati xyotax+radio fase II (forse già ad aprile, oppure dopo estate)
- comunicazione investitori Aequus (forse già ad aprile)
- Interim Extend pixantrone Fase III (giugno-luglio 07)
- Interim Rapid pixantrone Fae II/III (settembre-nvembre 2007)
- risultati xyotax+xeloda fase II (dicembre 07)

Se ne riparla nel 2008...
Dopo almeno altri due ADC.
Saluti
apuo

 ha scritto nel messaggio
news:SY0li.61446$%k.19...@twister2.libero.it...

il mercato stà comprando, e sta riassorbendo chi vende sulla notizia perchè
sono
attese altre notizie e di portata maggiore

 ha scritto nel messaggio
news:4694a10e$0$4797$4faf...@reader4.news.tin.it...

sta a vedere che e una news per far rastrellare meglio mani forti!!!
normalmente le news escono alle 13 come mai l'hanno piazzata questa
mattina!?!? sta a vedere che deve uscire roba + forte e
corposa...............

Cell Therapeutics, positivi i test su utilizzo pixantrone
Cell Therapeutics ha reso noto che i risultati interim dello studio clinico 


 ha scritto nel messaggio
news:V42li.50913$y05....@tornado.fastwebnet.it...

è molto atteso l'interim extend sul pix
poi la notizia sull'acquisizione di una nuova molecola
e sui partner per Aeequus

 corposa...............
aggiungo
la mossa di Bianco ha bloccato le banche shortiste
ora rimangono solo gli intraday, quindi come ieri si devono ricoprire
prima della chiusura

 La società si appresta a discutere con la FDA questi risultati, nonchè la 
